Q-omics provides the consensus-scored RPL35P9 profile across patient tissues and cancer cell-line models. RPL35P9 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, RPL35P9 is differentially expressed in 8, with the highest sampling consensus in UCEC. Additionally, RPL35P9 RNA expression shows 6,437 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight BLCA, UCEC, and STAD as cancer lineages where RPL35P9 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL35P9 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL35P9 survival associations across molecular data types. RPL35P9 RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL35P9 RNA expression–survival associations across cancer types. High RPL35P9 expression shows unfavorable associations in KIRC, COAD, ACC, KIRP and HNSC, but favorable associations in BLCA. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for RPL35P9 RNA expression.
This table summarizes RPL35P9 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in UCEC for RNA.
This table ranks reproducible tumor–normal expression differences for RPL35P9. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL35P9 shows lower tumor expression in UCEC, BRCA and THCA and higher tumor expression in HNSC, COAD and PRAD. The UCEC box plot shows higher RPL35P9 RNA expression in normal versus tumor tissue (log2 FC = −0.300, t-test p = .028).
This table shows molecular features associated with RPL35P9 in patient tissues and cancer cell lines. In patient samples, RPL35P9 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
